Analyst Price Targets — MIST
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| April 10, 2026 9:33 am | — | Raymond James | $6.00 | $2.04 | TheFly | Milestone Pharmaceuticals initiated with a Strong Buy at Raymond James |
| December 16, 2025 11:45 am | Mohit Bansal | Wells Fargo | $8.00 | $2.34 | TheFly | Milestone Pharmaceuticals price target raised to $8 from $4 at Wells Fargo |
| December 15, 2025 2:47 pm | Brandon Folkes | H.C. Wainwright | $8.00 | $2.58 | TheFly | Milestone Pharmaceuticals price target raised to $8 from $5 at H.C. Wainwright |
| April 22, 2022 4:54 am | — | Piper Sandler | $10.00 | $7.15 | Benzinga | Piper Sandler Upgrades Milestone Pharmaceuticals to Overweight, Raises Price Target to $10 |
Latest News for MIST
Registry Study Design Presented at the Preventive Cardiovascular Nurses Association 2026 Cardiovascular Nursing Symposium Registry Study Design Presented at the Preventive Cardiovascular Nurses Association 2026 Cardiovascular Nursing Symposium
MONTREAL and CHARLOTTE, N.C., April 07, 2026 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development of commercialization of innovative cardiovascular medicines, today announced that management will present at the 25 th Annual Needham Virtual Healthcare Conference to take place April 13 - 16, 2026.
MONTREAL and CHARLOTTE, N.C., April 02, 2026 (GLOBE NEWSWIRE) -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST) (the “Company” or “Milestone”), today announced that the Company granted equity awards, in the form of a total of 123,000 options (the “Options”) to purchase the Company's common shares, pursuant to the Company's 2021 Inducement Plan (the “Plan”), previously approved by the Company's Compensation Committee…
MONTREAL and CHARLOTTE, N.C., March 31, 2026 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that Express Scripts, one of the nation's largest pharmacy benefit managers, has added CARDAMYST™ (etripamil) nasal spray to its commercial national formularies, effective…
Milestone Pharmaceuticals Inc. (MIST) Q4 2025 Earnings Call Transcript
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for MIST.
U.S. House Trading
No House trades found for MIST.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.